Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18394
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.27
Last synced: 2026-10-16
Market Cap
$189.70M
Change (1 day)
-4.71%
Change (1 year)
839.61%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Dividend yield history for Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (stock symbol: RNAC) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Cartesian Therapeutics, Inc. (RNAC) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
